Biggest News Aggregation in the World
📰 Double Blind Phase News

Page 2 - Double Blind Phase News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Double Blind Phase. Real-time updates on events, politics, business and more.

AUA 2021: State-of-the-art Lecture: First and Second Line Therapy in Advanced and Metastatic Bladder Cancer: A Changing Paradigm

AUA 2021 First and Second Line Therapy in Advanced and Metastatic Bladder Cancer, metastatic urothelial cancer, MVAC chemotherapy, checkpoint immunotherapy, platinum-refractory advanced UC, Keynote-045 study, IMvigor130 trial, DANUBE trial, KEYNOTE-361 trial.
United States New York Thenappan Thenu Chandrasekar Morales Barrera Homet Moreno Cora Sternberg

Quercis Announces Special Protocol Assessment Agreement with U.S. Food and Drug Administration

Share this article Share this article ZUG, Switzerland, May 4, 2021 /PRNewswire/ -- Quercis Pharma AG, a private, clinical stage biopharmaceutical company leveraging its novel antithrombotic platform, today announces that it has entered into a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) for the protocol titled, "A Randomized, Placebo-Controlled, Double-Blind Phase 3 Trial Comparing, Relative to Placebo, the Effect of Isoquercetin on Thromboembo...
Jeffrey Zwicker Manon Veraart Quercis Pharma Stefan Wohlfeil Beth Israel Deaconess Medical Center Drug Administration

BioArctic : Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease published in peer-reviewed journal, Alzheimer's Research & Therapy

Message : Required fields Stockholm April 20, 2021 - BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimers Disease with Lecanemab, an Anti-Aβ Protofibril Antibody, in the peer-reviewed journal Alzheimers Research & Therapy. The manuscript describes results from Study 201, a Phase 2b proof-of-concept study that explored the impact of treatment w...
Oskar Bosson Gunilla Osswald Alzheimer Research Therapy Stockholm April Nasdaq Stockholm Double Blind Phase

Lecanemab (BAN2401) Phase 2b study in early Alzheimer's disease published in peer-reviewed journal, Alzheimer's Research & Therapy

Share this article Share this article STOCKHOLM, April 20, 2021 /PRNewswire/ -- BioArctic ABs (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced the publication of an article, A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimers Disease with Lecanemab, an Anti-Aβ Protofibril Antibody, in the peer-reviewed journal Alzheimers Research & Therapy.  The manuscript describes results from Study 201, a Phase 2b proof-of-concept study that explored the i...
Oskar Bosson Gunilla Osswald Alzheimer Research Therapy Nasdaq Stockholm Double Blind Phase Concept Clinical Trial

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science